Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Sep;24(9):2520-2531.
doi: 10.1007/s10461-020-02808-2.

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077

Elizabeth E Tolley  1 , Sahar Z Zangeneh  2 , Gordon Chau  2 , Joe Eron  3 , Beatriz Grinsztejn  4 , Hilton Humphries  5 , Albert Liu  6 , Marc Siegel  7 , Maseko Bertha  8 , Ravindre Panchia  9 , Sue Li  2 , Leslie Cottle  2 , Alex Rinehart  10 , David Margolis  10 , Andrea Jennings  11 , Marybeth McCauley  12 , Raphael J Landovitz  13
Affiliations
Randomized Controlled Trial

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077

Elizabeth E Tolley et al. AIDS Behav. 2020 Sep.

Abstract

Long-acting injectable PrEP could offer an alternative to daily oral PrEP, improve adherence and protection, if found acceptable, safe and effective. HPTN 077 evaluated injectable cabotegravir safety, tolerability and pharmacokinetics among HIV-uninfected males and females in sequentially-enrolled cohorts of two dosing strategies. We compared acceptability of product attributes, prevention preferences and future interest in injectable PrEP (FIIP) by region, sex-at-birth, arm and cohort and used multivariable analysis to identify FIIP determinants. Baseline injectable PrEP preferences were higher in non-U.S. sites and increased in both regions over time. In multivariable models, FIIP was most strongly associated with acceptability of product attributes, was higher in non-U.S. sites and more altruistic participants. Treatment arm and report of pain were not associated with FIIP. Injectable acceptability was highest in non-U.S. sites. Preferences for injectable versus other PrEP methods were higher among U.S. males than females, but higher among males and females in non-U.S. settings.

Keywords: Acceptability; Clinical trial; Females; HIV prevention; Injectable; Males; PrEP.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Acceptability of product attributes and physical experiences at week 6, by region and cohort 1
Fig. 2
Fig. 2
Acceptability of product attributes and physical experiences at week 6, by region and cohort 2
See this image and copyright information in PMC

References

    1. World Health Organization HIV/AIDS. 2018;19:2018.
    1. UNAIDS . UNAIDS Data 2019. Switzerland: UNAIDS; 2019.
    1. UN Women. Facts and figures: HIV and AIDS. UN Women; 2018.
    1. Centers for Disease Control and Prevention . Estimated HIV incidence and prevalence in the United States, 2010–2016. Atlanta: CDC; 2019.
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. doi: 10.1056/NEJMoa1108524. - DOI - PMC - PubMed

Publication types

MeSH terms